Abstract:

Objective To discuss the effects of intravitreal injection of ranibizumab in treatment of macular edema secondary to central retinal vein occlusion (CRVO). Design Prospective comparative case series. Participants 46 patients with macular edema secondary to CRVO (46 eyes). Method Using random stratified method, they were divided into control group (n=23 cases, 4 mg/0.1 ml intravitreal injection of Triamcinolone Acetonide) and study group (n=23 cases, 0.5 mg/0.05 ml intravitreal injection of ranibizumab). At 1 week, 4 weeks, 8 weeks, 12 weeks and 24 weeks after the treatment, the therapeutic effects were observed. Main Outcome Measures Best corrected visual acuity (BCVA), central macular thickness (CMT), intraocular pressure(IOP). Results (1) There was no statistically significant difference in terms of visual acuity improvement between the two groups (P=0.760, 0.765, 0.552, 0.767, 0.555); (2) The BCVA was significantly different at different time points within the two groups (F=4.373, P=0.000; F=3.472, P=0.008), but not significantly different between the two groups (P=1.000, 0.339, 0.484, 0.886, 0.502, 0.560); (3) The CMT was significantly different at different points withing the two groups (F=3.891, P=0.000; F=3.571, P=0.002), but not significantly different between the two groups (P=0.855, 0.869, 0.915, 0.892, 0.874, 0.564). (4) The IOP was not significantly different at different time points in the study group (F=2.341, P=0.137). The IOP was significantly different at different time points in the control group (F=2.569, P=0.049). However, at week 4 and week 24, the IOP value was significantly lower in the study group than the control group  (P=0.008, 0.042). At other time points the IOP was not significantly different(P=0.216, 0.161, 0.242). (5) During the follow-up, there was two patients(8.70%) in the control group showed elevated IOP. There was no complications recorded in the study group. Conclusion The intravitreal injection of ranibizumab for treatment of macular edema secondary to central retinal vein occlusion is effective and safe. (Ophthalmol CHN, 2017, 26: 116-119)

Key words: ranibizumab, central retinal vein occlusion, macular edema, triamcinolone acetonide